Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis

Drugs in R and D

Volumn 13, Issue 1, 2013, Pages 95-100

  Shono, Eisuke ^a  

^a Shono Rheumatology Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB;

ADULT; AGED; ANEMIA; ANKLE FRACTURE; ARTICLE; ASTHMA; BRONCHITIS; CLINICAL ARTICLE; CLINICAL PRACTICE; DAS28; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EMBOLISM; FEMALE; FEMUR FRACTURE; HUMAN; JAPANESE; KIDNEY DISEASE; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SAFETY; PERIPHERAL EDEMA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84876216261     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-013-0010-z     Document Type: Article

References (20)

1. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17(9 Suppl B):S14-8.
2. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-39.
3. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964-75.
4. Kievit W, Fransen J, Adang EMM, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford). 2011;50(1):196-203.
5. Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1-278.
6. Rahman MU, Buchanan J, Doyle MK, et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis. 2011;70(9):1631-40.
7. Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011;63(5):1200-10.
8. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis [Erratum appears in Arthritis Rheum. 2010;62(10):3005]. Arthritis Rheum. 2009;60(8):2272-83.
9. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study [Erratum appears in Ann Rheum Dis. 2011;70(1):238-9]. Ann Rheum Dis. 2010;69(6):1129-35.
10. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study [Erratum appears in Ann Rheum Dis. 2011;70(1):238]. Ann Rheum Dis. 2009;68(6):789-96.
11. Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010;2(4):428-39.
12. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial [Erratum appears in Lancet. 2009;374(9699):1422]. Lancet. 2009;374(9685):210-21.
13. Tanaka Y, Harigai M, Takeuchi T, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2012;71(6):817-24.
14. Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation. Simponi: Package insert. Japan 2011.
15. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81.
16. Takeuchi T, Harigai M, Tanaka Y, et al. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis. Epub 2012 Sep 18.
17. Seto Y, Tanaka E, Inoue E, et al. Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Mod Rheumatol. 2011;21(6):579-93.
18. Electronic Medicines Compendium (eMC). Methotrexate 5 mg tablets: Summary of prescribing information. 2012. http://www.medicines.org.uk/emc/medicine/ 22954/SPC#POSOLOGY. Accessed 2013 Mar 21.
19. Hutas G. Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies. Immunotherapy. 2010;2(4):453-60.
20. Zidi I, Bouaziz A, Mnif W, et al. Golimumab and malignancies: true or false association? Med Oncol. 2011;28(2):641-8.